Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

Jerusalem, Guy;Mariani, G.;Ciruelos, E. M.;Martin, M.;Tjan Heijnen, V. C. G.;Neven, P.;Gavila, J. G.;Michelotti, A.;Montemurro, F.;Generali, D.;Simoncini, E.;Lang, I.;Mardiak, J.;Naume, B.;Camozzi, M.;Lorizzo, K.;Bianchetti, S.;CONTE, PIERFRANCO

2016